PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : H

Records returned : 62 (on 19 Apr 2025 at 21:09:51).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Haem arginate
No Information Returned
Haemophilus influenzae B/meningococcal C
No Information Returned
Haemophilus influenzae vaccine
No Information Returned
Haemophilus influenzae/diptheria,tetanus,pertussis vaccine
No Information Returned
Halcinonide
No Information Returned
Halibut liver oil
No Information Returned
Halogenated phenols with phenol
No Information Returned
04.02.01
04.06.00
04.09.03
Haloperidol
Movement disorders
Blue
Formulations :
  • Capsules
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Includes tic disorders, tremors, Tourette's syndrome, choreas, Huntington's disease, Huntington's chorea
04.02.01
04.06.00
04.09.03
Haloperidol
Movement disorders
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Includes tic disorders, tremors, Tourette's syndrome, choreas, Huntington's disease, Huntington's chorea
04.02.01
04.06.00
04.09.03
Haloperidol
Nausea and vomiting (chemotherapy induced)
Red
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Haloperidol decanoate
No Information Returned
Halquinol
No Information Returned
Hamamalis
No Information Returned
Hamamelis
No Information Returned
Heat treated human factor IX
No Information Returned
Helicobacter pylori eradication therapy
No Information Returned
Heparin calcium
No Information Returned
Heparin flushes
No Information Returned
02.08.01
Heparin sodium
VTE treatment
Red
Formulations :
  • Intravenous injection (IV)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.01
Heparin sodium
Thromboprophylaxis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.01
Heparin sodium
IV catheter maintenance
Red
Formulations :
  • Intravenous flush
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Heparin sodium (Eye)
No Information Returned
Heparinoid
No Information Returned
Hepatitis A
No Information Returned
Hepatitis A/hepatitis B
No Information Returned
Hepatitis A/typhoid vaccine
No Information Returned
Hepatitis B
No Information Returned
Hepatitis B immunoglobulin
No Information Returned
Hexachlorophene
No Information Returned
12.03.04
Hexetidine
Oral hygiene
Non Formulary
Formulations :
  • Mouthwash
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Available to purchase for self care
Hexylresorcinol
No Information Returned
Hexylresorcinol and benzalkonium chloride
No Information Returned
Higher folic acid content
No Information Returned
Histamine dihydrocloride
No Information Returned
Histrelin acetate
No Information Returned
11.05.00
Homatropine hydrobromide
Uveitis
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
03.04.02
House dust mites allergen extract
Allergic rhinitis
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Human papillomavirus (Type 16,18)
No Information Returned
Human papillomavirus (Type 6,11,16,18)
No Information Returned
Humpapvirus(Type 6,11,16,18,31,33,45,52,58)
No Information Returned
Hyaluronic acid sodium
No Information Returned
Hyaluronidase
No Information Returned
02.05.01
Hydralazine hydrochloride
Hypertension
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Prescribing in primary care on specialist recommendation only. Reserved for severe / resistant hypertension.
02.05.01
Hydralazine hydrochloride
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Transfer of prescribing to primary care only after initiation and stabilisation by the specialist.
02.05.01
Hydralazine hydrochloride
Hypertension
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Hypertensive emergency (including pregnancy) or hypertension with renal complications
02.05.01
Hydralazine hydrochloride
Hypertension in pregnancy
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Hypertensive emergency (including pregnancy) or hypertension with renal complications
Hydrochlorothiazide
No Information Returned
Hydrocort sodiumphos
No Information Returned
06.03.02
12.03.01
Hydrocortisone
Oral ulceration
Green
Formulations :
  • Buccal tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Available to purchase for self care
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
2nd line option. Primary Care may initiate prescribing on request from the specialist endocrinology team.
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
2nd line option. Primary Care may initiate prescribing on request from the specialist endocrinology team.
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Granules in capsules for opening
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For infants / children on doses BELOW 5mg. Capsules for opening. 0.5mg, 1mg and 2mg only. Doses of 5mg or more - to halve a 10mg tablet and use lower strength capsules to achieve correct dose. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
See PAD for guidance on providing reserve supplies for dosing during acute illness
10mg tablets can be halved for doses of 5mg. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For patients on dose of 10mg AND unable to swallow solid dose forms. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Blue
Formulations :
  • Granules in capsules for opening
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For infants / children on doses BELOW 5mg. Capsules for opening. 0.5mg, 1mg and 2mg only. Doses of 5mg or more - to halve a 10mg tablet and use lower strength capsules to achieve correct dose. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
See PAD for guidance on providing reserve supplies for dosing during acute illness
Can be halved for doses of 5mg. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Blue
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For patients on dose of 10mg AND unable to swallow solid dose forms. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For use in infants and children where smaller doses are required.
06.03.02
12.03.01
Hydrocortisone
Anaphylaxis
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For use in infants and children where smaller doses are required.
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Non Formulary
Formulations :
  • Buccal tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
(MHRA drug safety update December 2018) https://www.gov.uk/drug-safety-update/hydrocortisone-muco-adhesive-buccal-tablets-should-not-be-used-off-label-for-adrenal-insufficiency-in-children-due-to-serious-risks
06.03.02
12.03.01
Hydrocortisone
Adrenal insufficiency
Non Formulary
Formulations :
  • Buccal tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
(MHRA drug safety update December 2018) https://www.gov.uk/drug-safety-update/hydrocortisone-muco-adhesive-buccal-tablets-should-not-be-used-off-label-for-adrenal-insufficiency-in-children-due-to-serious-risks
Hydrocortisone acetate
No Information Returned
Hydrocortisone butyrate
No Information Returned
Hydrocortisone sodium phosphate
No Information Returned
Hydrocortisone sodium succinate
No Information Returned
Hydrocortisone (Sodium succinate)
No Information Returned
12.03.04
13.11.06
Hydrogen peroxide
Post tonsillectomy haemorrhage
Red
Formulations :
  • Solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
6% solution, diluted for use as a mouthwash
Hydromorphone hydrochloride
No Information Returned
Hydrotalcite
No Information Returned
09.01.02
19.02.07
Hydroxocobalamin
post Bariatric surgery
Green (see narrative)
Formulations :
  • Intramuscular injection (IM)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not for use after gastric band surgery.
09.01.02
19.02.07
Hydroxocobalamin
Cyanide poisoning
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
https://www.toxbase.org/ .
Hydroxyapatite
No Information Returned
Hydroxycarbamide
No Information Returned
10.01.03
13.05.03
Hydroxychloroquine sulfate
Rheumatology indications
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.03
13.05.03
Hydroxychloroquine sulfate
Dermatology indications
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.03
13.05.03
Hydroxychloroquine sulfate
Alopecia
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Option for scarring alopecia
Hydroxyprogesterone caproate
No Information Returned
Hydroxyzine hydrochloride
No Information Returned
11.08.01
Hyetellose
Dry eyes
Non Formulary
Formulations :
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Hyoscine
No Information Returned
01.02.00
Hyoscine butylbromide
Muscle spasm
Green
Formulations :
  • Injection
  • Intramuscular injection (IM)
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Injection - serious risk of adverse effects in underlying cardiac disease
04.06.00
Hyoscine hydrobromide
Vestibular disorders
Green
Formulations :
  • Patches
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
Hyoscine hydrobromide
Hypersalivation in adults
Green
Formulations :
  • Patches
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Off-label use.
04.06.00
Hyoscine hydrobromide
Hypersalivation in adults
Green (see narrative)
Formulations :
  • Oral solution
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
100mcg per ml. Unlicensed formulation.
04.06.00
Hyoscine hydrobromide
Hypersalivation in children
Blue
Formulations :
  • Patches
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Off-label use. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team.
04.06.00
Hyoscine hydrobromide
Hypersalivation in children
Blue
Formulations :
  • Oral solution
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
300mcg/5ml. Unlicensed formulation. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team
11.08.01
Hypromellose
Dry eyes
Green
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild dry eye. Prescribe by brand (primary care) 1st line: Aapromel 0.3% or Aaculose 0.3% 2nd line: Lumecare 0.3%
11.08.01
Hypromellose
Dry eyes
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild dry eye. Prescribe by brand (primary care) 1st line = Evolve Hypromellose preservative free 0.3% 2nd line = Hypromol preservative free 0.3%
11.08.01
Hypromellose
Dry eyes
Green (see narrative)
Formulations :
  • Eye drops (unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild dry eye. Prescribe by brand (primary care) as Lumecare Singles Hypromellose. Reserved for occasional use where unit dose is required (e.g. to carry in a bag)
Hypromellose with phenylephrine
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More